Diversified by geography and business mix, Fresenius should be able to benefit from ongoing growth in treating ESRD patients worldwide in the long run. Although no pressure has emerged yet, the 2022 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback